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predicts peritonitis risk in chronic peritoneal
dialysis patients
Yu-Jen Su1†, Shang-Chih Liao1†, Ben-Chung Cheng1, Jyh-Chang Hwang2* and Jin-Bor Chen1*Abstract
Background: The aim of this study was to evaluate whether a high baseline level of high-sensitivity C-reactive
protein (hs-CRP) or changes in the level predicts the risk of peritonitis in patients on continuous ambulatory
peritoneal dialysis (CAPD).
Methods: A prospective, cross-sectional, case–control study was conducted in a single hospital-based PD unit. A
total of 327 patients were included in the study. Serum hs-CRP was measured annually for 2 years. Patients were
divided into 4 groups according to the changes in annual hs-CRP levels (at baseline and at 1 year intervals): group
1 (from <5 mg/L to <5 mg/L, n = 171), group 2 (from <5 mg/L to ≥5 mg/L, n = 45), group 3 (from ≥5 mg/L to <5
mg/L, n = 45), and group 4 (from ≥5 mg/L to ≥5 mg/L, n = 80). Demographics, biochemistry results, PD adequacy
indices, and peritonitis risk were compared between the groups.
Results: The initial serum albumin level was similar in the 4 groups (p = 0.12). There was a negative linear
correlation between the serial albumin change (Δalb) and serial hs-CRP change (Δhs-CRP; r = −0.154, p = 0.005). The
hazard ratio (HR) for peritonitis was significantly higher in group 2 (HR = 1, reference) than in group 4 (HR = 0.401,
95% CI 0.209 − 0.769). Group 2 had a greater serum albumin decline rate (Δalb: –3% ± 9%) and hs-CRP elevation
rate (Δhs-CRP: 835% ± 1232%) compared to those for the other groups.
Conclusions: A progressive increase in the hs-CRP level was associated with a corresponding decline in the serum
albumin level. Progressive rather than persistently high levels of serum hs-CRP predicted peritonitis risk in CAPD patients.
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Chronic inflammation remains an important adverse effect
in patients undergoing dialysis. Several markers of inflam-
mation have been used in clinical practice, including C-
reactive protein (CRP), interleukin-6, and tumor necrosis
factor. The CRP level is the most common indicator of
inflammatory status. CRP is a nonglycated protein pro-
duced by human hepatocytes in response to infection,
inflammation, or tissue damage. It is composed of 5
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reproduction in any medium, provided the orsymmetrical pentagonal structure with a molecular weight
of 105 kDa. CRP is present at very low levels in the normal
population. Levels < 1 mg/dL are considered insignificant,
levels from 1 to 10 mg/dl are considered moderately ele-
vated, and levels > 10 mg/dl are markedly elevated. Several
methods are currently available commercially for use in
clinical laboratories to measure CRP. The most commonly
used are immunonephelometric and immunoturbidimetric
assays. Recent studies have used newly developed high-
sensitivity tests for CRP. These ultrasensitive enzyme-
linked immunosorbent assays are capable of measuring
CRP at a concentration of 0.007 mg/L [1].
An elevated CRP level, which is a marker of malnutri-
tion, inflammation, and atherosclerosis (the MIA syn-
drome), is a risk factor for morbidity and mortality in the
general population [2] and in dialysis patients [3,4].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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CRP level and cardiovascular disease has been observed in
various studies [5-7], the relative contributions of CRP as
a marker, causative agent, or consequence of the MIA
syndrome are unclear in the dialysis population. In recent
literature, a strong emphasis has been placed on an
elevated CRP level as an important predictor of clinically
apparent inflammatory infectious disorders based on
cross-sectional analyses. However, the relationship be-
tween a single CRP measurement or variability in CRP
levels and the risk of peritonitis in peritoneal dialysis (PD)
patients remains uncertain. To the best of our knowledge,
no studies have published data on the prognostic value of
dynamic high-sensitivity CRP (hs-CRP) changes for peri-
tonitis risk in PD patients.
Peritonitis is a serious infectious and a major compli-
cation that accounts for a significant risk of mortality in
PD patients [8]. PD-related peritonitis, exit site infection,
and other infections are the main causes of chronic in-
flammation. A single elevated CRP level combined with
alterations in other acute-phase reactants is likely to be
an epiphenomenon. It is unknown whether this epiphe-
nomenon represents a chronic condition or whether it is
an indicator of an ongoing acute process. The objective
of the present study was to determine the prognostic
value and clinical correlations of longitudinal hs-CRP
variability in PD patients.
Methods
Patients and study design
A prospective, cross-sectional, case–control study design
was used. This study included all prevalent PD patients
from a PD institution at a medical center in southern
Taiwan. All patients underwent monthly assessments of
clinical and biochemical data from the start of the study in
October 2008 until the censor date in October 2011, which
was 2 years after the last patient was recruited into the
study. The exclusion criteria were the presence of a known
chronic inflammatory disease or major clinical events re-
quiring hospital admission (for example, peritonitis, or
other active infection) during the recruitment period from
October 2008 to October 2009. To avoid interference with
hs-CRP measurements, biochemical values that checked if
events occurring in the 1 month before October 2008 were
clinically active systemic, PD-associated infections, e.g. exit
site infection or inflammatory process, were excluded. hs-
CRP levels were measured in each patient at the time of
recruitment and annually thereafter. All patients partici-
pating in the study were followed regularly for 2 years. A
total of 327 patients were included in the final analysis. Pa-
tients were assigned to 4 groups according to the changes
in hs-CRP levels between baseline and after 1 year. Group
1 was defined by a hs-CRP level change from <5 mg/L at
baseline to <5 mg/L at 1 year (n = 171), group 2 from <5mg/L to ≥5 mg/L (n = 45), group 3 from ≥5 mg/L to <5
mg/L (n = 45), group 4 from ≥5 mg/L to ≥5 mg/L (n = 80).
The protocol for the present study was approved by the
Committee on Human Research at Kaohsiung Chang
Gung Memorial Hospital (CGMH-101-1595B), and all ex-
periments were conducted in accordance with the Declar-
ation of Helsinki. All participants provided informed
consent for participating in the study.
Laboratory measurement of hs-CRP
The hs-CRP level was assayed serially over the study
period using the immunoturbidimetric method (Spectra
East Laboratories, Rockleigh, NJ, USA). Serum hs-CRP <
5 mg/L was considered the cutoff level in our laboratory.
Statistical analyses
The chi-square test and analysis of variance (ANOVA)
with post hoc Bonferroni test were used for comparisons
between categorical and continuous variables between
groups, as shown in Table 1. Comparisons of hs-CRP
levels among the 4 groups were performed using Kruskal–
Wallis one-way ANOVA. Factors shown to be significant
(p < 0.10) by simple logistic regression analysis, such as
normalized protein catabolic rate (nPCR), body mass
index (BMI), diabetes mellitus (DM), sex, blood urea ni-
trogen (BUN), phosphate, potassium, age at the initiation
of the study, baseline albumin levels, and Δalbumin were
reanalyzed using stepwise forward multiple logistic regres-
sion tests (Table 2). These were performed to evaluate the
associations of characteristics of patients in group 2. Ac-
tual peritonitis-free rates in the 4 groups were determined
using the Kaplan–Meier method, and log-rank tests were
used to compare the cumulative peritonitis rates between
groups. After adjusting for covariant factors, including
DM, age during the study period, BMI, and the mean
serum albumin level, Cox proportional hazard analysis
was performed to determine the hazard ratios (HR) for
peritonitis development in the 4 groups (Figure 1B). Ex-
cept for the hs-CRP level (median, interquartile range), all
data are expressed as mean ± standard deviation. A p
value ≤ 0.05 was considered significant. Computations
were performed using the SPSS 17.0 package for Windows
(SPSS, Chicago, IL, USA).
Results
Demographic characteristics of the 4 groups of patients
As shown in Table 1, group 2 had a significantly lower
prevalence of DM compared to that in groups 3 and 4. Pa-
tients in group 4 had a higher mean BMI and length of
hospital stay but lower levels of nPCR compared to those
for patients in group 1. They also had significantly lower
levels of final serum albumin and serum potassium. Base-
line hs-CRP levels were significantly lower in groups 1
and 2 compared to the levels in groups 3 and 4. Group 4
Table 1 Baseline demographic characteristics of the 4 groups of patients
Group 1 Group 2 Group 3 Group 4
n = 171 n = 45 n = 31 n = 80
Demographic factors
Mean age at the start of the study 48 51 49 55
(range) (18–83) (20–80) (27–67) (24–80)
Male, % 39 44 52 52
Diabetes, % 7.0 6.7 25.8e 22.8e
PD vintage, years 4.6 ± 3.2 5.5 ± 3.7 4.1 ± 2.9 5.3 ± 3.1
Kt/V urea (Gotch formula) 2.14 ± 0.46 2.11 ± 0.35 2.03 ± 0.39 2.02 ± 0.33
nPCR, g/day 1.11 ± 0.23a 1.08 ± 0.22 1.02 ± 0.23 1.00 ± 0.24
Body mass index, kg/m2 21.9 ± 3.5b 22.8 ± 3.9 24.0 ± 3.0 24.3 ± 3.8
Clinical co-morbidity, %
Coronary artery disease 2 2 0 3
Congestive heart failure 6 7 3 9
Peripheral vascular disease 2 0 3 11
Stroke 2 4 10 9
Neoplasm 8 18 0 5
Chronic lung disease 5 2 6 8
Liver cirrhosis or hepatoma 3 0 10 4
No comorbidity, % 74 73 81 76
Recurrent peritonitis, % 5 9 0 6
Hospitalized stay, day 5 ± 11a 9 ± 14 8 ± 11 12 ± 21
Laboratory data
Baseline albumin, g/dL 3.80 ± 0.38 3.79 ± 0.39 3.68 ± 0.50 3.68 ± 0.42
Final albumin, g/dL 3.83 ± 0.35a,c 3.66 ± 0.39 3.87 ± 0.40 3.67 ± 0.43
Δ albumin, % 1% ± 7%c −3% ± 9% 6% ± 12% a,c 0% ± 11%
Baseline hs-CRP, mg/L, 1.49 2.10 f 9.75 g 11.6g
(Q1–Q3) (0.84 to 2.25) (1.30 to 3.61) (7.30 to 16.1) (7.85 to17.8)
Final hs-CRP, mg/L, 1.45 9.20 g 2.49f 12.8g
(Q1–Q3) (0.74 to 2.39) (7.29 to 12.1) (1.36 to 3.71) (7.89 to 25.1)
Δ hs-CRP, % −6h 416 −80h 0h
(Q1–Q3) (−38 to 49) (1.78 to 7.02) (−91 to −59) (−29 to 69)
Hematocrit, % 32.2 ± 4.3c 29.7 ± 4.6 30.9 ± 3.9 30.7 ± 4.0
Serum cholesterol, mg/dl 185 ± 39 177 ± 42 196 ± 59 184 ± 39
Serum triglyceride, mg/dL 145 ± 83 138 ± 93 158 ± 109 174 ± 93
Serum K, mEq/L 4.1 ± 0.7b 4.0 ± 0.6 3.9 ± 0.8 3.7 ± 0.6
BUN, mg/dL 66 ± 17 72 ± 19 62 ± 16 64 ± 15c
Serum Cr, mg/dL 12.1 ± 2.8 11.8 ± 3.0 11.6 ± 3.5 11.2 ± 2.6
Serum phosphorus, mg/dL 5.2 ± 1.1 5.6 ± 1.5 5.4 ± 1.5 5.0 ± 1.2c
Serum calcium, mg/dL 9.3 ± 0.8 9.3 ± 0.8 9.1 ± 0.9 9.4 ± 0.8
Abbreviations: PD peritoneal dialysis, nPCR normalized protein catabolism rate, BUN blood urea nitrogen, Cr creatinine.
Statistics:
ap < 0.05, bp < 0.001 vs. group 4 (ANOVA with Bonferroni tests), cp < 0.05, vs. group 2 (ANOVA with Bonferroni tests), ep < 0.05 vs. group 2 (Chi square tests),
fp < 0.05, gp < 0.001 vs. group 1 (Kruskal–Wallis one-way analysis of variance), hp < 0.001 vs. group 2 (Kruskal–Wallis one-way analysis of variance).
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Table 2 Logistic regression analysis of group 2
Simple Multiple*
95% CI 95% CI
OR Lower Upper Sig. OR Lower Upper Sig.
nPCR, g/day 1.172 0.313 4.381 0.814
BMI, kg/m2 1.001 0.92 1.089 0.989
BUN, mg/dL 1.025 1.007 1.043 0.007 1.019 1.000 1.039 0.055
Phosphate, mg/dL 1.35 1.051 1.733 0.019 1.232 0.948 1.601 0.119
Potassium, mmol/L 0.969 0.617 1.522 0.891
Hematocrit, % 0.907 0.845 0.974 0.007 0.92 0.855 0.99 0.026
age at study, year 1.009 0.985 1.034 0.471
Diabetes mellitus (=1) 0.459 0.135 1.554 0.211
Gender, (male gender = 1) 0.981 0.521 1.848 0.953
baseline albumin, g/dL 1.281 0.581 2.823 0.54
Δalbumin, % 0.945 0.911 0.981 0.003 0.947 0.912 0.982 0.004
Abbreviations: nPCR normalized protein catabolic rate, BMI body mass index, BUN blood urea nitrogen, Δalbumin, ratio of albumin concentration change,
* adjusted for: BUN phosphate, hematocrit, and Δalbumin.
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pared to those in the other 3 groups. Group 2 had signifi-
cantly lower final serum albumin levels, and higher final
hs-CRP levels compared to the levels in group 1. Although
group 4 had the highest final hs-CRP levels, the increment
of hs-CRP (Δhs-CRP) was the highest in group 2. Group 1
had higher baseline and final serum albumin levels but
lower final hs-CRP levels and Δhs-CRP compared to those
in group 2, although the initial serum albumin levels were
similar (p = 0.12).Relationship between the changes in serum albumin
(Δalb) and hs-CRP (Δhs-CRP) levels
In all patients, the mean serum albumin level was nega-
tively correlated with the mean hs-CRP level (r = −0.21, p
< 0.001). Furthermore, there was a negative linear correl-
ation between Δalb and Δhs-CRP (r = −0. 154, p = 0.005;
Figure 1A and B).Cox proportional hazard analysis for the evaluation of the
covariant factors related to peritonitis development
Log-rank tests showed no significant difference in the
peritonitis-free rates between the different groups, except
in group 2. The peritonitis-free rate in group 2 was sig-
nificantly lower than that in the other 3 groups (Figure 2).
After adjusting for covariant factors, including DM, age
at the time of the study, BMI, and the mean serum albu-
min level (Figure 2B), the HR for peritonitis development
was significantly higher in group 2 (HR = 1) than in
group 4 (HR = 0.401, 95% CI 0.209 − 0.769) and the other
2 groups.Characteristics of patients in group 2
The patients in group 2 were characterized by higher
BUN levels (OR 1.019; 95% CI 1.00 − 1.039) but lower
hematocrit (OR 0.92, 95% CI 0.855 − 0.99) and lower
serum albumin levels (OR 0.947, 95% CI 0.912 − 0.982)
compared to the levels in the other 3 groups Table 2. The
patients in group 2 also showed the highest serum albu-
min decline rate (Δalb: –3 ± 9%) and hs-CRP elevation
rate (Δhs-CRP: 835 ± 1232%).Discussion
The main finding of this study was that a progressive in-
crease in the hs-CRP level was associated with a corre-
sponding decline in the serum albumin level. Progressive
rather than a persistent high serum hs-CRP level pre-
dicted peritonitis risk in continuous ambulatory periton-
eal dialysis (CAPD) patients. Surprisingly, patients with
sustained high levels of hs-CRP had a similar risk of peri-
tonitis compared to that in patients with constant normal
hs-CRP values.
Approximately 30% of hemodialysis patients [9] and up
to 58% of PD patients [10] have high CRP levels. CRP is a
predictor of subsequent cardiovascular disease, cardiovas-
cular mortality, and all-cause mortality in the general
population [11] and in dialysis patients [5,12]. Most of
these published studies consider the rise in CRP combined
with alterations in other acute-phase reactants as an epi-
phenomenon. Regardless of its precise role, the serum
CRP level is a well-known indicator of inflammation, and
chronic inflammation remains an important adverse event
in patients undergoing dialysis. For patients on PD, PD-
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Figure 1 Relationship between the albumin and hs-CRP levels. In all patients as a group, there is a negative relationship between the mean
serum albumin level and the mean hs-CRP level (r = –0.21, p < 0.001) (A). There is also a negative linear correlation between Δalb and Δ/hs-CRP
(r = –0.154, p = 0.005) (B).
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the past decade, the relationship between inflammation
markers (e.g. an elevated CRP level), malnutrition (e.g.
hypoalbuminemia), and mortality has received much at-
tention. However, not all studies have been sufficiently
powered to assess this relationship. Moreover, an associ-
ation between elevated CRP levels and the risk of periton-
itis has not been investigated critically in PD patients. Our
study is the first report to address the association between
dynamic changes of hs-CRP and peritonitis risk in CAPD
patients.
Evidence that inflammation is responsible for regulating
serum albumin levels in dialysis patients was provided by
several cross-sectional studies [9,14,15]. An acute-phase
response, measured by CRP or serum amyloid A levels,
was significantly correlated with serum albumin levels inPD patients [16]. Because variations in serum albumin
levels are small, measurement of changes in CRP levels
may provide greater insight into the dynamics of nutri-
tional status and clinically relevant insults such as periton-
itis. The main finding of our study was that an increase in
the hs-CRP level was associated with a decrease in the
serum albumin level. Furthermore, the levels of nPCR
were higher in subjects with persistently low hs-CRP
levels than in those with persistently high hs-CRP levels.
These results reflected the impact of inflammatory status
on the nutritional status of the PD patients in this study.
Current hypotheses state that the increased CRP ob-
served in dialysis patients reflects the severity of an “in-
flammatory state,” caused by dialysis itself [17], vessel
inflammation due to atherosclerosis [5,18], and oxidative
stress generated by uremia [19]. Levels of inflammatory
Figure 2 Peritonitis-free rates between the different groups. The peritonitis-survival free rate is significantly lower in group 2 compared to
that in the other 3 groups (A). After adjusting for covariant factors, including DM, age at the time of the study, BMI, and the mean serum
albumin level, the HR for peritonitis is significantly higher in group 2 (reference group, HR = 1) compared to that in group 4 (HR = 0.401, 95% CI
0.209–0.769) and in the other 2 groups (B).
Su et al. BMC Nephrology 2013, 14:185 Page 6 of 8
http://www.biomedcentral.com/1471-2369/14/185and oxidative stress biomarkers are increased further in
hypoalbuminemic compared with normoalbuminemic dia-
lysis patients. Hypoalbuminemia, acute-phase inflamma-
tion, and oxidative stress may act synergistically to increase
cardiovascular morbidity and mortality risk in hemodialysis
patients [20]. However, little has been reported on oxida-
tive stress and antioxidant capacity in relation to serum al-
bumin in PD patients. In contrast, Kim et al. [21] showed
that oxidative stress was reduced in hypoalbuminemic PD
patients. Therefore, a well-designed study is necessary to
explore the relationship between oxidative stress and nutri-
tional indices in PD patients.
There is some evidence that CRP itself may have a
proinflammatory effect. For instance, CRP is able to acti-
vate the complement system and is a valuable marker ra-
ther than a contributor to the atherosclerotic process [22].
Furthermore, CRP is most helpful as a clinical parameteramong various proinflammatory markers for monitoring
microinflammation in patients with peritonitis [23]. The
additional presence of systemic inflammation (dynamic in-
crease in the hs-CRP level group), irrespective of its origin,
may be the factor “tipping the scales” toward a cata-
strophic peritonitis event, possibly by directly activating
mesothelium cells, which is the first line of defense against
foreign particles and chemicals in the peritoneal cavity.
Increased synthesis of proinflammatory cytokines and
matrix proteins is observed after the activation of infiltrat-
ing and resident peritoneal cells, leading to morphological
changes such as reduplication of the basement membrane,
induction of epithelial-to-mesenchymal transdifferen-
tiation, a breakdown of the basement membrane, and
their migration into the submesothelium [24]. A loss of
the protective mesothelium allows PD fluid and toxins
released by bacteria to induce the activation of peritoneal
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variably increases the peritonitis risk [25].
In the present study, persistently high serum hs-CRP
levels (group 4) were not associated with a higher periton-
itis risk, and the underlying mechanisms remained un-
clear. PD patients are exposed to persistent low-grade
inflammation, and levels of serum inflammatory markers
vary substantially over time under the influence of mul-
tiple processes such as transient infection, comorbidities,
and the intermittent stimulus of dialysis. The differences
in the condition of individual PD patients resulted in
inter-individual variability in serum hs-CRP levels. The
cardiovascular co-morbidity rate in group 4 was relatively
high compared to that in the other 3 groups. This factor
might result in sustained high hs-CRP levels, but may not
be associated with an increased peritonitis risk in the fol-
lowing year. The results of the present study further
enforced the importance of serial hs-CRP measurements.
Although chronic kidney disease should be considered
in association with the inflammatory status, the extent of
inflammation was not consistent. Therefore, a single mea-
surement of inflammatory markers such as hs-CRP is not
suitable to assess the true condition of patients. Regular
monitoring of inflammatory markers is more reasonable
for accurate clinical prediction. Snaedal et al. [26] used
median or mean CRP levels measured weekly over a 3-
month period to assess 224 patients who were undergoing
hemodialysis. The results showed that an elevation of 1
mg/L in median or mean CRP levels was correlated with a
1.2–1.3% increase in the HR for all-cause mortality. Other
studies based on consecutive measurement of CRP levels
in dialysis patients showed that those with persistently ele-
vated CRP levels had worse all-cause mortality than those
with persistently low CRP levels or CRP elevations and/or
decreases [27-29]. In the present study, the PD-related
peritonitis-free period was lower in patients with progres-
sive hs-CRP elevation than in the other patients, which is
in agreement with the results of previous studies showing
the association between all-cause mortality and changes in
the CRP level. Because the CRP measurements in the
present study were not performed during an active in-
fectious period, our findings imply that a temporal or
sub-clinical inflammatory reaction was ongoing when
the measurement was taken. Therefore, it may provide
an early warning sign to clinical physicians to closely
observe ominous infectious situations such as PD-
related peritonitis.
To the best of our knowledge, this is the first report
describing a stratified fluctuation of hs-CRP levels related
to PD-peritonitis risk. However, our study had some
limitations. First, because hs-CRP measurements were
performed annually for 2 years, it is possible that subtle
inflammatory reactions occurring during the study period
were not detected. Second, the sample size was relativesmall. Third, this was a cross-sectional prospective study,
and selection bias might preclude other morbid patients.
Conclusions
In conclusion, our data demonstrated an association be-
tween a progressive increase in hs-CRP levels and periton-
itis risk in CAPD patients. The serum albumin level was
negatively correlated with the hs-CRP level in these pa-
tients, implying that the extent of the decline in the serum
albumin level reflects the progress of the sub-clinical in-
flammation and/or infection. This may explain the associ-
ation between the progressive elevation of hs-CRP levels
and the development of peritonitis in CAPD patients. Our
results showed that persistent high levels of hs-CRP were
not related to peritonitis risk. Although we suspect that
adaptation and/or accommodation to mild sub-clinical in-
flammation may be a contributing factor, the underlying
mechanism remains to be elucidated.
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